324 / 884
l
No clinical or biochemical benefits
from the addition of ADT in LR en fIR
l
Beneficial in bPFS
–
in most patients with HR disease using LDR
–
some patients with uIR
–
In patients with low D90 or low BED
l
Not beneficial in CSS
–
A very small absolute benefit (2%) to CSS was found in only a few studies and
was predominantly with 3-modality treatment vs PB monotherapie
l
No OS survival benefit was found in any study
l
However: three studies reported on a detriment to OS using ADT
(cave: older patients, existing CV disease)